FSB Premier Wealth Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.59M Sell
16,970
-249
-1% -$38.2K 0.81% 33
2025
Q4
$2.37M Buy
17,219
+1,121
+7% +$147K 0.75% 39
2025
Q3
$2.06M Buy
16,098
+1,774
+12% +$216K 0.68% 42
2025
Q2
$1.73M Buy
14,324
+2,236
+18% +$252K 0.62% 47
2025
Q1
$1.35M Buy
12,088
+793
+7% +$84.4K 0.53% 54
2024
Q4
$1.1M Buy
11,295
+1,896
+20% +$202K 0.44% 56
2024
Q3
$1.08M Buy
9,399
+1,773
+23% +$201K 0.44% 62
2024
Q2
$812K Buy
7,626
+2,651
+53% +$266K 0.37% 68
2024
Q1
$481K Buy
4,975
+897
+22% +$92K 0.22% 93
2023
Q4
$412K Buy
4,078
+1,136
+39% +$110K 0.21% 99
2023
Q3
$300K Buy
2,942
+410
+16% +$41.6K 0.17% 113
2023
Q2
$256K Sell
2,532
-104
-4% -$10.4K 0.14% 127
2023
Q1
$243K Buy
2,636
+148
+6% +$12.9K 0.13% 127
2022
Q4
$226K Buy
+2,488
New +$210K 0.12% 136
2022
Q1
Sell
-1,566
Closed -$137K 381
2021
Q4
$137K Buy
+1,566
New +$130K 0.06% 152

Other funds holding NVS

FSB Premier Wealth Management's NVS Position: Q1 2026 in Review

FSB Premier Wealth Management reduced its Novartis (NVS) stake by 1.4% in Q1 2026, selling an estimated $38.2K and leaving 16,970 shares worth $2.59M. The position accounts for 0.81% of the portfolio, ranked #33.

FSB Premier Wealth Management first reported a position in NVS in Q4 2021 and has held it in 15 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • FSB Premier Wealth Management held 16,970 shares of Novartis worth $2.59M as of Q1 2026.
  • FSB Premier Wealth Management sold 249 Novartis shares in Q1 2026, an estimated $38.2K.
  • Novartis made up 0.81% of FSB Premier Wealth Management's portfolio in Q1 2026, its #33 holding.
  • FSB Premier Wealth Management first reported a position in Novartis in Q4 2021 and has held it in 15 quarters since.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on FSB Premier Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.